MS4A3 Inhibitors
MS4A3 inhibitors encompass a range of chemical compounds that influence specific signaling pathways or biological processes that MS4A3 is directly involved in. Wortmannin and LY294002 are potent inhibitors of the PI3K/AKT pathway. This inhibition can result in decreased phosphorylation of AKT, likely reducing the activation of downstream proteins that are regulated by AKT, including MS4A3 if it is part of this pathway. Rapamycin and AZD8055 target the mTOR pathway, which is downstream of AKT. By disrupting mTORC1 and mTORC2 complexes, these inhibitors could contribute to the reduced activity of MS4A3 if it is influenced by mTOR signaling. U0126 and PD98059 target the MEK/ERK pathway, potentially leading to a decrease in MS4A3 activity if it is regulated through this pathway.
Chemicals such as SB203580 and SP600125 act on the MAPK pathways, with SB203580 specifically inhibiting p38 MAPK and SP600125targeting JNK. By dampening these kinases' activities, the signaling that may control MS4A3's function is also diminished. Dasatinib and PP2, as Src family kinase inhibitors, have the potential to decrease MS4A3 activity by inhibiting signaling pathways that are activated by Src kinases, which could indirectly affect MS4A3. Meanwhile, BAY 11-7082's inhibition of NF-κB can lower MS4A3 activity by preventing NF-κB from activating genes that may be necessary for MS4A3's function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3K). It impedes the PI3K/AKT pathway, which can lead to decreased phosphorylation and activation of various downstream targets, potentially including MS4A3 if it is regulated by this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a chemical inhibitor of PI3K, hindering the PI3K/AKT signaling pathway. By reducing AKT phosphorylation, it can indirectly inhibit the activity of proteins regulated by this pathway, such as MS4A3. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTORC1 complex, which is downstream of the PI3K/AKT pathway. It can decrease the activity of proteins that are affected by mTORC1 signaling, possibly including MS4A3. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, leading to reduced ERK pathway signaling. This pathway can regulate a variety of cellular functions, and inhibition of ERK signaling could lead to decreased MS4A3 activity if it is an ERK pathway target. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that can reduce the activity of proteins that are regulated by the p38 MAPK signaling pathway. If MS4A3 is modulated by this pathway, its activity could be indirectly diminished. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the c-Jun N-terminal kinase (JNK), which can decrease the signaling through the JNK pathway, potentially reducing the activity of proteins like MS4A3 if they are regulated by this pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor that can suppress downstream signaling pathways, such as those involving PI3K/AKT. This suppression could lead to reduced MS4A3 activity if MS4A3 is influenced by Src kinase signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is another Src family kinase inhibitor that can inhibit signaling through pathways that involve Src kinases. If MS4A3 is modulated by Src family kinase activity, PP2 could then indirectly decrease MS4A3 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 can lead to reduced ERK signaling and possibly decrease MS4A3 activity if it is an ERK-regulated protein. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 is an NF-κB inhibitor that can impede the activation of NF-κB, a transcription factor that regulates the expression of various genes. If MS4A3 is under the control of NF-κB, its activity could be indirectly decreased. | ||||||